The era of the immunoglobulin A Fc receptor FcαRI; its function and potential as target in disease

Immunological Reviews

Volumn 268, Issue 1, 2015, Pages 123-138

  Aleyd, Esil ^a   Heineke, Marieke H ^a   van Egmond, Marjolein ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Autoimmune diseases; Cancer; CD89; IgA; Inflammation; Neutrophil

Indexed keywords

FC ALPHA RECEPTOR I; FC RECEPTOR; IMMUNOGLOBULIN A; UNCLASSIFIED DRUG; FC(ALPHA) RECEPTOR; LEUKOCYTE ANTIGEN; LIGAND; PROTEIN BINDING;

ANTIBODY TITER; ANTIGEN ANTIBODY COMPLEX; AUTOIMMUNE DISEASE; BLISTER; CANCER IMMUNOTHERAPY; HOMEOSTASIS; HUMAN; IMMUNOSTIMULATION; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; LEUKOCYTE ACTIVATION; LEUKOCYTE MIGRATION; MUCOSAL IMMUNITY; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; TISSUE INJURY; ULCERATIVE COLITIS; ANIMAL; ANTIBODY SPECIFICITY; CHEMISTRY; GENE EXPRESSION REGULATION; GENETICS; IMMUNE SYSTEM DISEASES; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MICROBIOLOGY; MUCOSA; NEOPLASMS; PROTEIN DOMAIN;

ANIMALS; ANTIGENS, CD; GENE EXPRESSION REGULATION; HUMANS; IMMUNE SYSTEM DISEASES; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOTHERAPY; LIGANDS; MUCOUS MEMBRANE; NEOPLASMS; ORGAN SPECIFICITY; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; RECEPTORS, FC; SIGNAL TRANSDUCTION;

EID: 84945264927     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12337     Document Type: Review

References (130)

1. Macpherson AJ, Geuking MB, McCoy KD. Homeland security: IgA immunity at the frontiers of the body. Trends Immunol 2012;33:160-167.
2. Pamer EG. Immune responses to commensal and environmental microbes. Nat Immunol 2007;8:1173-1178.
3. Woof JM, Kerr MA. The function of immunoglobulin A in immunity. J Pathol 2006;208:270-282.
4. Yel L. Selective IgA deficiency. J Clin Immunol 2010;30:10-16.
5. Reljic R. In search of the elusive mouse macrophage Fc-alpha receptor. Immunol Lett 2006;107:80-81.
6. Van Egmond M, Bakema JE, Woof JM. Fc Receptors in Mucosal Immunology. 4th edn. New York: Elsevier, Inc., 2015.
7. Maliszewski CR, March CJ, Schoenborn MA, Gimpel S, Shen L. Expression cloning of a human Fc receptor for IgA. J Exp Med 1990;172:1665-1672.
8. Monteiro RC, Van De Winkel JG. IgA Fc receptors. Annu Rev Immunol 2003;21:177-204.
9. Nimmerjahn F, Ravetch JV. Fcgamma receptors: old friends and new family members. Immunity 2006;24:19-28.
10. Martin AM, Kulski JK, Witt C, Pontarotti P, Christiansen FT. Leukocyte Ig-like receptor complex (LRC) in mice and men. Trends Immunol 2002;23:81-88.
11. Geissmann F, et al. A subset of human dendritic cells expresses IgA Fc receptor (CD89), which mediates internalization and activation upon cross-linking by IgA complexes. J Immunol 2001;166:346-352.
12. Monteiro RC, Kubagawa H, Cooper MD. Cellular distribution, regulation, and biochemical nature of an Fc alpha receptor in humans. J Exp Med 1990;171:597-613.
13. Smith PD, et al. Intestinal macrophages lack CD14 and CD89 and consequently are down-regulated for LPS- and IgA-mediated activities. J Immunol 2001;167:2651-2656.
14. van Egmond M, et al. FcalphaRI-positive liver Kupffer cells: reappraisal of the function of immunoglobulin A in immunity. Nat Med 2000;6:680-685.
15. Qian K, Xie F, Gibson AW, Edberg JC, Kimberly RP, Wu J. Functional expression of IgA receptor FcalphaRI on human platelets. J Leukoc Biol 2008;84:1492-1500.
16. Voehringer D. Protective and pathological roles of mast cells and basophils. Nat Rev 2013;13:362-375.
17. Monteiro RC, Cooper MD, Kubagawa H. Molecular heterogeneity of Fc alpha receptors detected by receptor-specific monoclonal antibodies. J Immunol 1992;148:1764-1770.
18. Chevailler A, Monteiro RC, Kubagawa H, Cooper MD. Immunofluorescence analysis of IgA binding by human mononuclear cells in blood and lymphoid tissue. J Immunol 1989;142:2244-2249.
19. Bakema JE, et al. c-Jun activating binding protein 1 binds to the IgA receptor and modulates protein levels of FcalphaRI and FcRgamma-chain. Eur J Immunol 2010;40:2035-2040.
20. Yin N, Peng M, Xing Y, Zhang W. Intracellular pools of FcalphaR (CD89) in human neutrophils are localized in tertiary granules and secretory vesicles, and two FcalphaR isoforms are found in tertiary granules. J Leukoc Biol 2007;82:551-558.
21. Herr AB, Ballister ER, Bjorkman PJ. Insights into IgA-mediated immune responses from the crystal structures of human FcalphaRI and its complex with IgA1-Fc. Nature 2003;423:614-620.
22. Woof JM, Burton DR. Human antibody-Fc receptor interactions illuminated by crystal structures. Nat Rev 2004;4:89-99.
23. Carayannopoulos L, Hexham JM, Capra JD. Localization of the binding site for the monocyte immunoglobulin (Ig) A-Fc receptor (CD89) to the domain boundary between Calpha2 and Calpha3 in human IgA1. J Exp Med 1996;183:1579-1586.
24. van Spriel AB, et al. Mac-1 (CD11b/CD18) is essential for Fc receptor-mediated neutrophil cytotoxicity and immunologic synapse formation. Blood 2001;97:2478-2486.
25. Kiyoshi M, et al. Structural basis for binding of human IgG1 to its high-affinity human receptor FcgammaRI. Nat Commun 2015;6:6866.
26. Ramsland PA, et al. Structural basis for Fc gammaRIIa recognition of human IgG and formation of inflammatory signaling complexes. J Immunol 2011;187:3208-3217.
27. Reterink TJ, et al. Size-dependent effect of IgA on the IgA Fc receptor (CD89). Eur J Immunol 1997;27:2219-2224.
28. Xue J, Zhao Q, Zhu L, Zhang W. Deglycosylation of FcalphaR at N58 increases its binding to IgA. Glycobiology 2010;20:905-915.
29. Lu J, et al. Recognition and functional activation of the human IgA receptor (FcalphaRI) by C-reactive protein. Proc Natl Acad Sci USA 2011;108:4974-4979.
30. Lu J, Marjon KD, Mold C, Marnell L, Du Clos TW, Sun P. Pentraxins and IgA share a binding hot-spot on FcalphaRI. Protein Sci 2014;23:378-386.
31. Bakema JE, et al. Inside-out regulation of Fc alpha RI (CD89) depends on PP2A. J Immunol 2008;181:4080-4088.
32. Bracke M, et al. Differential effects of the T helper cell type 2-derived cytokines IL-4 and IL-5 on ligand binding to IgG and IgA receptors expressed by human eosinophils. J Immunol 1997;159:1459-1465.
33. Bracke M, Lammers JW, Coffer PJ, Koenderman L. Cytokine-induced inside-out activation of FcalphaR (CD89) is mediated by a single serine residue (S263) in the intracellular domain of the receptor. Blood 2001;97:3478-3483.
34. Weisbart RH, Kacena A, Schuh A, Golde DW. GM-CSF induces human neutrophil IgA-mediated phagocytosis by an IgA Fc receptor activation mechanism. Nature 1988;332:647-648.
35. Ginsberg MH, Partridge A, Shattil SJ. Integrin regulation. Curr Opin Cell Biol 2005;17:509-516.
36. Smith AD, Streilein RD, Hall RP 3rd. Neutrophil CD11b, L-selectin and Fc IgA receptors in patients with dermatitis herpetiformis. Br J Dermatol 2002;147:1109-1117.
37. Morton HC, et al. Functional association between the human myeloid immunoglobulin A Fc receptor (CD89) and FcR gamma chain. Molecular basis for CD89/FcR gamma chain association. J Biol Chem 1995;270:29781-29787.
38. van Egmond M, et al. Human immunoglobulin A receptor (FcalphaRI, CD89) function in transgenic mice requires both FcR gamma chain and CR3 (CD11b/CD18). Blood 1999;93:4387-4394.
39. Pfefferkorn LC, Yeaman GR. Association of IgA-Fc receptors (Fc alpha R) with Fc epsilon RI gamma 2 subunits in U937 cells. Aggregation induces the tyrosine phosphorylation of gamma 2. J Immunol 1994;153:3228-3236.
40. Bakema JE, et al. Signaling through mutants of the IgA receptor CD89 and consequences for Fc receptor gamma-chain interaction. J Immunol 2006;176:3603-3610.
41. Bakema JE, van Egmond M. The human immunoglobulin A Fc receptor FcalphaRI: a multifaceted regulator of mucosal immunity. Mucosal Immunol 2011;4:612-624.
42. Wines BD, Trist HM, Ramsland PA, Hogarth PM. A common site of the Fc receptor gamma subunit interacts with the unrelated immunoreceptors FcalphaRI and FcepsilonRI. J Biol Chem 2006;281:17108-17113.
43. Honorio-Franca AC, Launay P, Carneiro-Sampaio MM, Monteiro RC. Colostral neutrophils express Fc alpha receptors (CD89) lacking gamma chain association and mediate noninflammatory properties of secretory IgA. J Leukoc Biol 2001;69:289-296.
44. Shen L, et al. Presentation of ovalbumin internalized via the immunoglobulin-A Fc receptor is enhanced through Fc receptor gamma-chain signaling. Blood 2001;97:205-213.
45. Wu J, et al. FcalphaRI (CD89) alleles determine the proinflammatory potential of serum IgA. J Immunol 2007;178:3973-3982.
46. Ra C, Jouvin MH, Blank U, Kinet JP. A macrophage Fc gamma receptor and the mast cell receptor for IgE share an identical subunit. Nature 1989;341:752-754.
47. Lang ML, et al. IgA Fc receptor (FcalphaR) cross-linking recruits tyrosine kinases, phosphoinositide kinases and serine/threonine kinases to glycolipid rafts. Biochem J 2002;364:517-525.
48. Jouvin MH, Adamczewski M, Numerof R, Letourneur O, Valle A, Kinet JP. Differential control of the tyrosine kinases Lyn and Syk by the two signaling chains of the high affinity immunoglobulin E receptor. J Biol Chem 1994;269:5918-5925.
49. Launay P, Lehuen A, Kawakami T, Blank U, Monteiro RC. IgA Fc receptor (CD89) activation enables coupling to syk and Btk tyrosine kinase pathways: differential signaling after IFN-gamma or phorbol ester stimulation. J Leukoc Biol 1998;63:636-642.
50. Cantrell DA. Phosphoinositide 3-kinase signalling pathways. J Cell Sci 2001;114:1439-1445.
51. Lang ML, Glennie MJ, Kerr MA. Human neutrophil Fc alpha R and Fc gamma RIIa but not Fc gamma RIIIb generate intracellular calcium signals which trigger the respiratory burst. Biochem Soc Trans 1997;25:333S.
52. Jabril-Cuenod B, et al. Syk-dependent phosphorylation of Shc. A potential link between FcepsilonRI and the Ras/mitogen-activated protein kinase signaling pathway through SOS and Grb2. J Biol Chem 1996;271:16268-16272.
53. Park RK, Izadi KD, Deo YM, Durden DL. Role of Src in the modulation of multiple adaptor proteins in FcalphaRI oxidant signaling. Blood 1999;94:2112-2120.
54. Pasquier B, et al. Identification of FcalphaRI as an inhibitory receptor that controls inflammation: dual role of FcRgamma ITAM. Immunity 2005;22:31-42.
55. Ben Mkaddem S, Rossato E, Heming N, Monteiro RC. Anti-inflammatory role of the IgA Fc receptor (CD89): from autoimmunity to therapeutic perspectives. Autoimmun Rev 2013;12:666-669.
56. Pfirsch-Maisonnas S, et al. Inhibitory ITAM signaling traps activating receptors with the phosphatase SHP-1 to form polarized "inhibisome" clusters. Sci Signal 2011;4:ra24.
57. Ben Mkaddem S, et al. Shifting FcgammaRIIA-ITAM from activation to inhibitory configuration ameliorates arthritis. J Clin Invest 2014;124:3945-3959.
58. Blank U, Launay P, Benhamou M, Monteiro RC. Inhibitory ITAMs as novel regulators of immunity. Immunol Rev 2009;232:59-71.
59. Brinkmann V, et al. Neutrophil extracellular traps kill bacteria. Science (New York, NY) 2004;303:1532-1535.
60. Aleyd E, et al. IgA enhances NETosis and release of neutrophil extracellular traps by polymorphonuclear cells via Fcalpha receptor I. J Immunol 2014;192:2374-2383.
61. Wehrli M, et al. Human IgA Fc receptor FcalphaRI (CD89) triggers different forms of neutrophil death depending on the inflammatory microenvironment. J Immunol 2014;193:5649-5659.
62. van der Steen L, et al. Immunoglobulin A: Fc(alpha)RI interactions induce neutrophil migration through release of leukotriene B4. Gastroenterology 2009;137:2018-2029.
63. Kerr MA. The structure and function of human IgA. Biochem J 1990;271:285-296.
64. Johansen FE, et al. Absence of epithelial immunoglobulin A transport, with increased mucosal leakiness, in polymeric immunoglobulin receptor/secretory component-deficient mice. J Exp Med 1999;190:915-922.
65. Mazanec MB, Kaetzel CS, Lamm ME, Fletcher D, Nedrud JG. Intracellular neutralization of virus by immunoglobulin A antibodies. Proc Natl Acad Sci USA 1992;89:6901-6905.
66. Burns JW, Siadat-Pajouh M, Krishnaney AA, Greenberg HB. Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity. Science (New York, NY) 1996;272:104-107.
67. Corthesy B, et al. Rotavirus anti-VP6 secretory immunoglobulin A contributes to protection via intracellular neutralization but not via immune exclusion. J Virol 2006;80:10692-10699.
68. Wright A, Lamm ME, Huang YT. Excretion of human immunodeficiency virus type 1 through polarized epithelium by immunoglobulin A. J Virol 2008;82:11526-11535.
69. Hur EM, et al. Inhibitory effect of HIV-specific neutralizing IgA on mucosal transmission of HIV in humanized mice. Blood 2012;120:4571-4582.
70. Seaton KE, et al. HIV-1 specific IgA detected in vaginal secretions of HIV uninfected women participating in a microbicide trial in Southern Africa are primarily directed toward gp120 and gp140 specificities. PLoS ONE 2014;9:e101863.
71. Rochereau N, et al. Secretory IgA as a vaccine carrier for delivery of HIV antigen to M cells. Eur J Immunol 2015;45:773-779.
72. Bakema JE, van Egmond M. Immunoglobulin A: a next generation of therapeutic antibodies? mAbs 2011;3:352-361.
73. Vidarsson G, et al. Activity of human IgG and IgA subclasses in immune defense against Neisseria meningitidis serogroup B. J Immunol 2001;166:6250-6256.
74. Launay P, et al. Fcalpha receptor (CD89) mediates the development of immunoglobulin A (IgA) nephropathy (Berger's disease). Evidence for pathogenic soluble receptor-Iga complexes in patients and CD89 transgenic mice. J Exp Med 2000;191:1999-2009.
75. van Egmond M, Hanneke van Vuuren AJ, van de Winkel JG. The human Fc receptor for IgA (Fc alpha RI, CD89) on transgenic peritoneal macrophages triggers phagocytosis and tumor cell lysis. Immunol Lett 1999;68:83-87.
76. Hellwig SM, van Spriel AB, Schellekens JF, Mooi FR, van de Winkel JG. Immunoglobulin A-mediated protection against Bordetella pertussis infection. Infect Immun 2001;69:4846-4850.
77. Balu S, et al. A novel human IgA monoclonal antibody protects against tuberculosis. J Immunol 2011;186:3113-3119.
78. Delacroix DL, Elkom KB, Geubel AP, Hodgson HF, Dive C, Vaerman JP. Changes in size, subclass, and metabolic properties of serum immunoglobulin A in liver diseases and in other diseases with high serum immunoglobulin A. J Clin Invest 1983;71:358-367.
79. Montenegro V, Monteiro RC. Elevation of serum IgA in spondyloarthropathies and IgA nephropathy and its pathogenic role. Curr Opin Rheumatol 1999;11:265-272.
80. Nahm DH, Kim HY, Park HS. Elevation of specific immunoglobulin A antibodies to both allergen and bacterial antigen in induced sputum from asthmatics. Eur Respir J 1998;12:540-545.
81. Zhang C, Zeng X, Li Z, Wang Z, Li S. Immunoglobulin A nephropathy: current progress and future directions. Transl Res 2015;166:134-144.
82. Berthelot L, et al. Transglutaminase is essential for IgA nephropathy development acting through IgA receptors. J Exp Med 2012;209:793-806.
83. Papista C, et al. Gluten exacerbates IgA nephropathy in humanized mice through gliadin-CD89 interaction. Kidney Int 2015 [Epub ahead of print].
84. Liu C, et al. Targeted IgA Fc receptor I (FcalphaRI) therapy in the early intervention and treatment of pristane induced lupus nephritis in mice. Clin Exp Immunol 2015 [Epub ahead of print].
85. Tissandie E, et al. Both IgA nephropathy and alcoholic cirrhosis feature abnormally glycosylated IgA1 and soluble CD89-IgA and IgG-IgA complexes: common mechanisms for distinct diseases. Kidney Int 2011;80:1352-1363.
86. Valerius T, Wurflein D, Stockmeyer B, Repp R, Kalden JR, Gramatzki M. Activated neutrophils as effector cells for bispecific antibodies. Cancer Immunol Immunother 1997;45:142-145.
87. Nowak UM, Newkirk MM. Rheumatoid factors: good or bad for you? Int Arch Allergy Immunol 2005;138:180-188.
88. Humphreys JH, et al. Rheumatoid factor and anti-citrullinated protein antibody positivity, but not level, are associated with increased mortality in patients with rheumatoid arthritis: results from two large independent cohorts. Arthritis Res Ther 2014;16:483.
89. Rossato E, et al. Reversal of arthritis by human monomeric IgA through receptor mediated SHP-1 inhibitory pathway. Arthritis Rheumatol (Hoboken, NJ) 2015;67:1766-1777.
90. Pai S, Pai L, Birkenfeldt R. Correlation of serum IgA rheumatoid factor levels with disease severity in rheumatoid arthritis. Scand J Rheumatol 1998;27:252-256.
91. Rantapaa-Dahlqvist S, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003;48:2741-2749.
92. Karimifar M, Moussavi H, Babaei M, Akbari M. The association of immunoglobulin A, immunoglobulin G and anti-cyclic citrullinated peptide antibodies with disease activity in seronegative rheumatoid arthritis patients. J Res Med Sci 2014;19:823-826.
93. Jonsson T, et al. Raised IgA rheumatoid factor (RF) but not IgM RF or IgG RF is associated with extra-articular manifestations in rheumatoid arthritis. Scand J Rheumatol 1995;24:372-375.
94. He Y, Zha Q, Liu D, Lu A. Relations between serum IgA level and cartilage erosion in 436 cases of rheumatoid arthritis. Immunol Invest 2007;36:285-291.
95. Bobbio-Pallavicini F, et al. High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis. Ann Rheum Dis 2007;66:302-307.
96. Sakthiswary R, Shaharir SS, Mohd Said MS, Asrul AW, Shahril NS. IgA rheumatoid factor as a serological predictor of poor response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis. Int J Rheumatic Dis 2014;17:872-877.
97. Anquetil F, Clavel C, Offer G, Serre G, Sebbag M. IgM and IgA rheumatoid factors purified from rheumatoid arthritis sera boost the Fc receptor- and complement-dependent effector functions of the disease-specific anti-citrullinated protein autoantibodies. J Immunol 2015;194:3664-3674.
98. Grespan R, et al. CXCR2-specific chemokines mediate leukotriene B4-dependent recruitment of neutrophils to inflamed joints in mice with antigen-induced arthritis. Arthritis Rheum 2008;58:2030-2040.
99. Davidson EM, Rae SA, Smith MJ. Leukotriene B4, a mediator of inflammation present in synovial fluid in rheumatoid arthritis. Ann Rheum Dis 1983;42:677-679.
100. Ahmadzadeh N, Shingu M, Nobunaga M, Tawara T. Relationship between leukotriene B4 and immunological parameters in rheumatoid synovial fluids. Inflammation 1991;15:497-503.
101. Chen M, et al. Neutrophil-derived leukotriene B4 is required for inflammatory arthritis. J Exp Med 2006;203:837-842.
102. Mihai S, Sitaru C. Immunopathology and molecular diagnosis of autoimmune bullous diseases. J Cell Mol Med 2007;11:462-481.
103. van der Steen LP, et al. Blocking Fcalpha receptor I on granulocytes prevents tissue damage induced by IgA autoantibodies. J Immunol 2012;189:1594-1601.
104. Sur Chowdhury C, Giaglis S, Walker UA, Buser A, Hahn S, Hasler P. Enhanced neutrophil extracellular trap generation in rheumatoid arthritis: analysis of underlying signal transduction pathways and potential diagnostic utility. Arthritis Res Ther 2014;16:R122.
105. Schmidt E, Zillikens D. Pemphigoid diseases. Lancet 2013;381:320-332.
106. Sitaru C, Zillikens D. Mechanisms of blister induction by autoantibodies. Exp Dermatol 2005;14:861-875.
107. Sardy M, Karpati S, Merkl B, Paulsson M, Smyth N. Epidermal transglutaminase (TGase 3) is the autoantigen of dermatitis herpetiformis. J Exp Med 2002;195:747-757.
108. Wines BD, Hogarth PM. IgA receptors in health and disease. Tissue Antigens 2006;68:103-114.
109. ten Hove W, Houben LA, Raaijmakers JA, Koenderman L, Bracke M. Rapid selective priming of FcalphaR on eosinophils by corticosteroids. J Immunol 2006;177:6108-6114.
110. Pleass RJ, Lang ML, Kerr MA, Woof JM. IgA is a more potent inducer of NADPH oxidase activation and degranulation in blood eosinophils than IgE. Mol Immunol 2007;44:1401-1408.
111. Guandalini S, Assiri A. Celiac disease: a review. JAMA Pediatr 2014;168:272-278.
112. Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu Rev Immunol 2010;28:573-621.
113. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007;448:427-434.
114. Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 2011;474:298-306.
115. Palm NW, et al. Immunoglobulin A coating identifies colitogenic bacteria in inflammatory bowel disease. Cell 2014;158:1000-1010.
116. Bakema JE, et al. Antibody-opsonized bacteria evoke an inflammatory dendritic cell phenotype and polyfunctional Th cells by cross-talk between TLRs and FcRs. J Immunol 2015;194:1856-1866.
117. Deo YM, Sundarapandiyan K, Keler T, Wallace PK, Graziano RF. Bispecific molecules directed to the Fc receptor for IgA (Fc alpha RI, CD89) and tumor antigens efficiently promote cell-mediated cytotoxicity of tumor targets in whole blood. J Immunol 1998;160:1677-1686.
118. Valerius T, et al. FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy. Blood 1997;90:4485-4492.
119. van Egmond M, Bakema JE. Neutrophils as effector cells for antibody-based immunotherapy of cancer. Semin Cancer Biol 2013;23:190-199.
120. Duchez S, et al. Premature replacement of mu with alpha immunoglobulin chains impairs lymphopoiesis and mucosal homing but promotes plasma cell maturation. Proc Natl Acad Sci USA 2010;107:3064-3069.
121. Beyer T, Lohse S, Berger S, Peipp M, Valerius T, Dechant M. Serum-free production and purification of chimeric IgA antibodies. J Immunol Methods 2009;346:26-37.
122. Dechant M, Valerius T. IgA antibodies for cancer therapy. Crit Rev Oncol Hematol 2001;39:69-77.
123. Otten MA, et al. FcR gamma-chain dependent signaling in immature neutrophils is mediated by FcalphaRI, but not by FcgammaRI. J Immunol 2007;179:2918-2924.
124. Otten MA, et al. Immature neutrophils mediate tumor cell killing via IgA but not IgG Fc receptors. J Immunol 2005;174:5472-5480.
125. Stockmeyer B, et al. Triggering Fc alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy. J Immunol 2000;165:5954-5961.
126. Otten MA, et al. Enhanced FcalphaRI-mediated neutrophil migration towards tumour colonies in the presence of endothelial cells. Eur J Immunol 2012;42:1815-1821.
127. Bakema JE, et al. Targeting FcalphaRI on polymorphonuclear cells induces tumor cell killing through autophagy. J Immunol 2011;187:726-732.
128. Boross P, et al. IgA EGFR antibodies mediate tumour killing in vivo. EMBO Mol Med 2013;5:1213-1226.
129. Kelton W, et al. IgGA: a "cross-isotype" engineered human Fc antibody domain that displays both IgG-like and IgA-like effector functions. Chem Biol 2014;21:1603-1609.
130. Borrok MJ, et al. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcalphaRI (CD89) binding. mAbs 2015;7:743-751.